Multidrug-resistant E.coli outcompete harmless strains to take over the gut, study reveals

Different strains of E.coli can outcompete one another to take over the gut, a new study reveals.

Johnson & Johnson’s TREMFYA gains FDA approval

With the new approval, Johnson and Johnson’s TREMFYA now has three indications. Credit: Skorzewiak/Shutterstock. Johnson & Johnson has announced that the US Food and Drug

September 12, 2024

Clinical Trials and Development Services for the Pharmaceutical Industry

Share this article Clinical trials are essential for licensing pharmaceutical products, so carrying them out requires operational excellence. Formulation development services are crucial for developing

April 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Multidrug-resistant E.coli outcompete harmless strains to take over the gut, study reveals

Johnson & Johnson’s TREMFYA gains FDA approval

Clinical Trials and Development Services for the Pharmaceutical Industry

Asymptomatic throat carriage is the key to transmission of Group A Streptococcus infections

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe